Forma and Novartis Form Cancer Drug Collaboration

Xconomy Boston — 

Forma Therapeutics, a Cambridge, MA-based biotech firm, said this morning that it has landed a drug-discovery collaboration with Swiss drug giant Novartis. Novartis, which has previously invested in Forma through its Novartis Option Fund, is tapping the biotech startup to apply its cell-based screening platform to discover inhibitor treatments that target protein-to-protein interactions in cancer. Financial terms of the deal and specific drug targets involved weren’t disclosed.